Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chest discomfort, Chills, Cough, Dysphonia
Clinical narrative: Body aches; heaviness in chest; cough; sweats; Day 2 increasing throughout the day (unable to work)=fever, chills, nausea, headache and fatigue severe from evening to next day; Day 2 increasing throughout the day (unable to work)=fever, chills, nausea, headache and fatigue severe from evening to next day; Day 2 increasing throughout the day (unable to work)=fever, chills, nausea, headache and fatigue severe from evening to next day; Day 2 increasing throughout the day (unable to work)=fever, chills, nausea, headache and fatigue severe from evening to next day; Day 2 increasing throughout the day (unable to work)=fever; Booster: day 1 mild right arm soreness at injection site;; Booster; Dry/Hoarse voice; Sore ness at injection site/mild swelling; This is a spontaneous report from a contactable other hcp. A 54-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: not reported), dose 3 intramuscular, administered in Arm Right on 07Oct2021 18:00 (at the age of 54-years-old) as dose 3 (booster), single for covid-19 immunisation (at the age of 54-years-old). Medical history included hypothyroid, Allergies to Sulfa. Concomitant medication included influenza vaccine (FLU VACCINE VII) taken for an unspecified indication on 04Oct2021; thyroid (ARMOUR THYROID) taken for hypothyroidism. Patient had no known allergies. Concomitant medication included influenza vaccine (FLU VACCINE VII) taken for an unspecified indication on 04Oct2021; thyroid (ARMOUR THYROID) taken for hypothyroidism, start and stop date were not reported. Historical Vaccine included BNT162B2 (Batch/Lot No: EL1284) as dose 1 on 31Dec2021 at 10:00 and dose 2 of BNT162B2 (Batch/Lot No: EL3249) on 22Jan2021 at 10:00 for Covid-19 Immunization (at the age of 54-years-old). The patient experienced "booster: day 1 mild right arm soreness at injection site; on 07Oct2021 20:00, day 2 increasing throughout the day (unable to work)=fever, chills, nausea, headache and fatigue severe from evening to next day on 08Oct2021, sweats on 09Oct2021, heaviness in chest on 10Oct2021, cough on 10Oct2021, body aches on 2021, dry/hoarse voice on 2021, sore ness at injection site/mild swelling on 2021. The patient underwent lab tests and procedures which included body temperature: 103.5 on 2021, sars-cov-2 test: negative on 25Sep2021 Nasal Swab. Therapeutic measures were taken as a result of nausea and fever. Fever and headache was treated with Tylenol.  Events were reported as Day 3= severe headache OTC not lessening symptoms; low grade fever/chills/sweats; day 4=mild fever/sweats, fatigue, heaviness in chest and cough. The patient was not COVID prior vaccination and tested for COVID post vaccination. Patient did not require medical intervention and did not visit Emergency Department. There was multiorgan involvement which affected Respiratory, Cardiovascular, Dermatological/Mucosal and Gastrointestinal. Bilateral wheeze/bronchospasm was mild congestion/cough. Stridor: No, Upper airway swelling: No, Respiratory distress: No, Tachypnoea: No, Increased use of accessory respiratory muscles: No, Recession: No, Cyanosis: No, Grunting: No, Dry cough: No. Sensation of throat closure: No, Sneezing: No, Rhinorrhoea: No Other: No. Cardiovascular: Unknown Measured hypotension: Unknown Shock: No, Tachycardia: No, Capillary refill time>3sec: No, Reduced central pulse volume: No, Decreased level of consciousness: No, Loss of consciousness: No, Other: No, Generalized urticaria (hives): No, Generalized erythema: No, Angioedema (not hereditary): No, Generalized pruritus with skin rash: No, Generalized pruritus without skin rash: No, Generalized prickle sensation: No, Localized injection site urticaria: Yes, soreness at injection site/mild swelling Red and itchy eyes: No, Other: No. Gastrointestinal: yes (Nausea) Diarrhea: No Abdominal pain: No Nausea: No Vomiting: No took Zofran-very nauseous day2 and 3. The events require the initiation of new medication or other treatment or procedure. Outcome of the events was recovering.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up